Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-१.४८%
१,०७५.०५
-१६.४६
-१.४८%
—१,०९१.५११,०९०.४०१,०९०.४०१,०७४.८९——
SIXC
Communications
SIXC
Communications
SIXC
-०.४५%
६०७.३८
-२.७३
-०.४५%
—६१०.११६१०.११६१०.२९६०६.१७——
SIXE
Energy
SIXE
Energy
SIXE
+०.६७%
१,२४६.३२
+८.३४
+०.६७%
—१,२३७.९८१,२३७.८३१,२५२.४११,२२५.०३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.९७%
१,७२७.८३
-१६.८८
-०.९७%
—१,७४४.७११,७४०.९५१,७४७.२९१,७२१.५७——
SIXM
Financials
SIXM
Financials
SIXM
-०.७८%
६३५.१७
-५.०१
-०.७८%
—६४०.१८६३९.९२६४३.१९६३४.७३——
SIXR
Staples
SIXR
Staples
SIXR
-०.९४%
८४१.५६
-८.०२
-०.९४%
—८४९.५८८४५.२७८५१.६८८४१.१७——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.७०%
२१५.९५
-१.५३
-०.७०%
—२१७.४८२१७.४८२१८.१६२१५.८५——
SIXT
Technology
SIXT
Technology
SIXT
+०.०१%
३,२६०.९५
+०.२६
+०.०१%
—३,२६०.६९३,२७३.३६३,२८७.८१३,२४०.७८——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.६५%
९३६.३३
-६.१२
-०.६५%
—९४२.४५९३९.३९९४८.८०९३४.०४——
SIXV
Health care
SIXV
Health care
SIXV
-०.४९%
१,४५९.६५
-७.१५
-०.४९%
—१,४६६.८०१,४६४.७०१,४६७.१९१,४५८.३६——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-०.९१%
२,३७५.६३
-२१.८७
-०.९१%
—२,३९७.५०२,३९५.०३२,४१२.०१२,३७०.६४——
ABVX:NASDAQ
Abivax SA
US$ ११६.१५
-१.२४%
(-१.४६) 1D
मे ४, १३:१७:२३ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
US$ ११८.३१
High
US$ ११९.०४
Low
US$ ११४.८५
Mkt. cap
८.०० अरब
Volume
३.४५ लाख
52-wk high
US$ १४८.८३
52-wk low
US$ ५.५९
Shares outstanding
७.९३ करोड
No. of employees
६९
News stories
From sources across the web
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees६९
Founded२०१३ डिसेम्बर ४
Headquarters-
Sector-
Websiteabivax.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
२०२५ मार्च
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
Revenue
९.७० लाख
१०.४७ लाख
६.३९ लाख
१९.१४ लाख
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
३.९३ करोड
३.८६ करोड
५.५४ करोड
४.४४ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
८८.९३ लाख
८९.४४ लाख
२.७३ करोड
२.७७ करोड
Operating expense
४.८२ करोड
४.७५ करोड
८.१४ करोड
७.३६ करोड
Total operating expenses
४.८२ करोड
४.७५ करोड
८.१४ करोड
७.३६ करोड
Operating income
-४.७२ करोड
-४.६५ करोड
-८.०७ करोड
-७.१६ करोड
Other non operating income
४.३१ लाख
२६.५५ लाख
-७.४२ करोड
-४९.६० लाख
EBT including unusual items
-५.२४ करोड
-४.८४ करोड
-१५.३४ करोड
-७.६१ करोड
EBT excluding unusual items
-५.१३ करोड
-४.८४ करोड
-१५.३४ करोड
-८.०८ करोड
Income tax expense
-
-
-
५८.४८ लाख
Effective tax rate
-
-
-
-७.६८%
Other operating expenses
-२४.०० हजार
-४६.०० हजार
-१४.०४ लाख
१४.७४ लाख
Net income
-५.२४ करोड
-४.८४ करोड
-१५.३४ करोड
-८.२० करोड
Net profit margin
-५,३९८.९७%
-४,६२४.०७%
-२३,९९९.६९%
-४,२८२.१३%
Earnings per share
-
-
-
-
Interest and investment income
८.५९ लाख
१.९० लाख
३३.६१ लाख
११.९० लाख
Interest expense
-४५.३५ लाख
-३५.२१ लाख
-४२.१३ लाख
-१.५३ करोड
Net interest expenses
-३६.७६ लाख
-३३.३१ लाख
-८.५२ लाख
-१.४१ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
-४.७१ करोड
-४.६५ करोड
-८.०६ करोड
-७.०८ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer